Edwards Lifesciences Corporation
EW
Clasificación en acciones
#483
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Precio por acción
$87.29
Última sincronización: 2026-10-19
Capitalización bursátil
$50.31B
Cambio (1 día)
0.96%
Cambio (1 año)
15.94%
País
US
Comercio Edwards Lifesciences Corporation (EW)
Categoría
Healthcare
Ganancias de Edwards Lifesciences Corporation (EW)
Ganancias en Jun 2026 TTM: $1.42B
Secondo gli ultimi rapporti finanziari di Edwards Lifesciences Corporation, gli utili attuali della società sono $1.42B. Nel 2024, la società ha registrato un utile di $1.55B, un aumento con respecto a agli utili del 2023, che erano di $1.37B. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Edwards Lifesciences Corporation desde 2000 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $1.42B | 11.37% |
| 2025 | $1.27B | -17.78% |
| 2024 | $1.55B | 12.80% |
| 2023 | $1.37B | -22.35% |
| 2022 | $1.77B | 3.84% |
| 2021 | $1.70B | 85.67% |
| 2020 | $916.70M | -21.41% |
| 2019 | $1.17B | 53.20% |
| 2018 | $761.40M | -26.43% |
| 2017 | $1.03B | 40.25% |
| 2016 | $737.90M | 18.56% |
| 2015 | $622.40M | -45.59% |
| 2014 | $1.14B | 122.01% |
| 2013 | $515.30M | 31.76% |
| 2012 | $391.10M | 37.91% |
| 2011 | $283.60M | 5.74% |
| 2010 | $268.20M | -11.89% |
| 2009 | $304.40M | 85.16% |
| 2008 | $164.40M | 9.75% |
| 2007 | $149.80M | -13.06% |
| 2006 | $172.30M | 47.64% |
| 2005 | $116.70M | 287.71% |
| 2004 | $30.10M | -67.56% |
| 2003 | $92.80M | 65.71% |
| 2002 | $56.00M | -722.22% |
| 2001 | $-9.00M | -96.53% |
| 2000 | $-259.00M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $7.51B | 429.84% |
US
|
|
| $5.56B | 292.42% |
IE
|
|
| $5.15B | 263.15% |
US
|
|
| $3.86B | 172.36% |
US
|
|
| - | - |
DE
|
